Human Genome reports once-monthly Zalbin data

Human Genome Sciences Inc. (NASDAQ:HGSI) reported interim data from a Phase IIb trial of once-monthly Zalbin albinterferon alfa-2b in treatment-naive patients with HCV genotype 2 or 3. Daily oral ribavirin plus monthly injections of 900, 1,200 or 1,500 ug Zalbin led to a sustained virologic response (SVR) at week 12 in 76%, 75% and 81% of patients, respectively, vs. 82% of patients receiving ribavirin plus weekly injections of Pegasys peginterferon alfa-2a. Partner Novartis AG (NYSE:NVS; SIX:NOVN) conducted the open-label, active-controlled, dose-ranging trial, which enrolled 391 patients. ...